(Q37987789)

26 August 2017

Cyclin dependent kinases in cancer: potential for therapeutic intervention (English)

1 reference

26 August 2017

Miriam Canavese

1

1 reference

PubMed ID

22361734

26 August 2017

Loredana Santo

series ordinal

2

1 reference

PubMed ID

22361734

26 August 2017

Noopur Raje

series ordinal

3

1 reference

26 August 2017

1 May 2012

1 reference

Cancer Biology and Therapy

26 August 2017

1 reference

26 August 2017

13

1 reference

26 August 2017

451-457

1 reference

26 August 2017

7

1 reference

Cyclin-dependent kinase inhibitors as potential targeted anticancer agents

26 August 2017

1 reference

Cyclin D-dependent kinases, INK4 inhibitors and cancer

21 January 2018

1 reference

Complexities in the development of cyclin-dependent kinase inhibitor drugs

21 January 2018

1 reference

CDK inhibitors: cell cycle regulators and beyond

21 January 2018

1 reference

Cell cycle kinases as therapeutic targets for cancer

21 January 2018

1 reference

Mammalian cyclin-dependent kinases

21 January 2018

1 reference

Cyclin E ablation in the mouse

21 January 2018

1 reference

A small molecule based on the pRb2/p130 spacer domain leads to inhibition of cdk2 activity, cell cycle arrest and tumor growth reduction in vivo

21 January 2018

1 reference

Cyclin-dependent kinase pathways as targets for cancer treatment

21 January 2018

1 reference

TFIIH is negatively regulated by cdk8-containing mediator complexes

21 January 2018

1 reference

AT7519, A novel small molecule multi-cyclin-dependent kinase inhibitor, induces apoptosis in multiple myeloma via GSK-3beta activation and RNA polymerase II inhibition.

21 January 2018

1 reference

Cyclins and cdks in development and cancer: a perspective

21 January 2018

1 reference

Cyclins and CDKS in development and cancer: lessons from genetically modified mice

21 January 2018

1 reference

Progress in the evaluation of CDK inhibitors as anti-tumor agents

21 January 2018

1 reference

Peptides or small molecules? Different approaches to develop more effective CDK inhibitors.

21 January 2018

1 reference

Genetic alterations of cyclins, cyclin-dependent kinases, and Cdk inhibitors in human cancer

21 January 2018

1 reference

Proliferation of cancer cells despite CDK2 inhibition.

21 January 2018

1 reference

Targeting the cell cycle: a new approach to cancer therapy

21 January 2018

1 reference

Targeting the cell division cycle in cancer: CDK and cell cycle checkpoint kinase inhibitors

21 January 2018

1 reference

Cyclin-dependent kinase 2 is essential for meiosis but not for mitotic cell division in mice.

21 January 2018

1 reference

Flavopiridol, an inhibitor of transcription: implications, problems and solutions

21 January 2018

1 reference

Phase I clinical and pharmacokinetic trial of the cyclin-dependent kinase inhibitor flavopiridol

21 January 2018

1 reference

Phase II study of flavopiridol in patients with advanced colorectal cancer

21 January 2018

1 reference

Phase II trial of flavopiridol, a cyclin dependent kinase inhibitor, in untreated metastatic malignant melanoma

21 January 2018

1 reference

A Phase II trial of flavopiridol (NSC #649890) in patients with previously untreated metastatic androgen-independent prostate cancer

21 January 2018

1 reference

Phase I dose-finding study of weekly docetaxel followed by flavopiridol for patients with advanced solid tumors.

21 January 2018

1 reference

A phase I clinical trial of the sequential combination of irinotecan followed by flavopiridol

21 January 2018

1 reference

Phase 1 trial of flavopiridol combined with cisplatin or carboplatin in patients with advanced malignancies with the assessment of pharmacokinetic and pharmacodynamic end points.

21 January 2018

1 reference

Phase I study of flavopiridol in combination with Paclitaxel and Carboplatin in patients with non-small-cell lung cancer

21 January 2018

1 reference

UCN-01 in combination with topotecan in patients with advanced recurrent ovarian cancer: a study of the Princess Margaret Hospital Phase II consortium

21 January 2018

1 reference

Phase I trial of the cyclin-dependent kinase inhibitor and protein kinase C inhibitor 7-hydroxystaurosporine in combination with Fluorouracil in patients with advanced solid tumors.

21 January 2018

1 reference

Roscovitine and other purines as kinase inhibitors. From starfish oocytes to clinical trials

21 January 2018

1 reference

A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days

21 January 2018

1 reference

N-&-N, a new class of cell death-inducing kinase inhibitors derived from the purine roscovitine

21 January 2018

1 reference

Cyclin E as a prognostic and predictive marker in breast cancer

21 January 2018

1 reference

A phase 1 study of SNS-032 (formerly BMS-387032), a potent inhibitor of cyclin-dependent kinases 2, 7 and 9 administered as a single oral dose and weekly infusion in patients with metastatic refractory solid tumors.

21 January 2018

1 reference

Molecular and pharmacodynamic characteristics of the novel multi-target tumor growth inhibitor ZK 304709.

21 January 2018

1 reference

A novel therapeutic combination using PD 0332991 and bortezomib: study in the 5T33MM myeloma model.

21 January 2018

1 reference

Molecular and cellular effects of multi-targeted cyclin-dependent kinase inhibition in myeloma: biological and clinical implications

21 January 2018

1 reference

Molecular pathogenesis and a consequent classification of multiple myeloma

21 January 2018

1 reference

Advances in biology of multiple myeloma: clinical applications

21 January 2018

1 reference

Mutually exclusive cyclin-dependent kinase 4/cyclin D1 and cyclin-dependent kinase 6/cyclin D2 pairing inactivates retinoblastoma protein and promotes cell cycle dysregulation in multiple myeloma

21 January 2018

1 reference

Seliciclib (CYC202 or R-roscovitine), a small-molecule cyclin-dependent kinase inhibitor, mediates activity via down-regulation of Mcl-1 in multiple myeloma

21 January 2018

1 reference

Preclinical activity of P276-00, a novel small-molecule cyclin-dependent kinase inhibitor in the therapy of multiple myeloma

21 January 2018

1 reference

Seliciclib (CYC202, R-Roscovitine) induces cell death in multiple myeloma cells by inhibition of RNA polymerase II-dependent transcription and down-regulation of Mcl-1

21 January 2018

1 reference

The glamour and gloom of glycogen synthase kinase-3

21 January 2018

1 reference

Identification of N-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H-pyrazole-3-carboxamide (AT7519), a novel cyclin dependent kinase inhibitor using fragment-based X-ray crystallography and structure based drug design

21 January 2018

1 reference

Biological characterization of AT7519, a small-molecule inhibitor of cyclin-dependent kinases, in human tumor cell lines

21 January 2018

1 reference

Future novel single agent and combination therapies

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.4161/CBT.19589

1 reference

26 August 2017

1 reference

PubMed ID

22361734